CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 31 enrolled
Drug / intervention
insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02100475
NCT02100475Phase 3Completed
CompareCT.gov

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)

Novo Nordisk A/S·interventional·Posted Apr 1, 2014·Updated Jan 20, 2017

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide and insulin aspart for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 31 participants across 60 sites in 10 countries.

Detailed Summary

This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification. This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Australia, Greece, Hungary, Mexico, Russia, Slovakia, South Africa, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 1, 2014
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.3 years ago

Interventions

insulin degludec/liraglutidedrug

Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin. Dose individually adjusted.

insulin aspartdrug

Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.